Advertisement
UK markets closed

  • NIKKEI 225

    38,835.10
    +599.03 (+1.57%)
     

  • HANG SENG

    18,479.37
    -98.93 (-0.53%)
     

  • CRUDE OIL

    78.75
    +0.27 (+0.34%)
     

  • GOLD FUTURES

    2,323.80
    -7.40 (-0.32%)
     

  • DOW

    38,899.03
    +46.76 (+0.12%)
     

  • Bitcoin GBP

    50,721.82
    +44.09 (+0.09%)
     

  • CMC Crypto 200

    1,320.70
    -44.43 (-3.25%)
     

  • NASDAQ Composite

    16,386.30
    +37.06 (+0.23%)
     

  • UK FTSE All Share

    4,522.99
    +53.90 (+1.21%)
     
Money:

The retirement income gap no-one is talking about

People are living longer than ever before and this can impact how you plan for retirement

Is Innoviva (INVA) Stock Outpacing Its Medical Peers This Year?

Zacks Equity Research
·2-min read

Investors focused on the Medical space have likely heard of Innoviva (INVA), but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.

Innoviva is one of 889 companies in the Medical group. The Medical group currently sits at #1 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.

The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. INVA is currently sporting a Zacks Rank of #1 (Strong Buy).

Over the past three months, the Zacks Consensus Estimate for INVA's full-year earnings has moved 13.46% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.

ADVERTISEMENT

Our latest available data shows that INVA has returned about 0.95% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of -0.87% on a year-to-date basis. This means that Innoviva is outperforming the sector as a whole this year.

Looking more specifically, INVA belongs to the Large Cap Pharmaceuticals industry, which includes 15 individual stocks and currently sits at #16 in the Zacks Industry Rank. This group has gained an average of 0.76% so far this year, so INVA is performing better in this area.

Investors with an interest in Medical stocks should continue to track INVA. The stock will be looking to continue its solid performance.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Innoviva, Inc. (INVA) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research